The Food and Drug Administration has approved a new generic drug for treating bacterial and protozoan infections, according to the agency.
A new treatment for bacterial infections of the vagina is now available, the drug's manufacturer said.
Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.
Research has shown that 3-in-4 women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced, citing an independent survey commissioned for Monistat.
Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that...